This article is part of our "Best Stocks for 2011" series where our Foolish writers pick their top stock ideas for the year ahead. Click here to see a review of last year's picks and our 12 recommendations for the year ahead.
Warren Buffett loves huge moats. He also likes to invest early and often, and the Oracle of Omaha buys when others are selling.
With all these investing strategies in mind, I wouldn't be surprised to see Berkshire Hathaway buying a large stake in Intuitive Surgical
Intuitive Surgical builds surgical robots. The da Vinci assisted-surgery system is the only platform of its kind, and it's surrounded by a massive pile of ironclad patents. The only real competition was eliminated in 2003, when the company merged with Computer Motion. Yahoo! Finance is usually pretty good at digging up rivals for comparison purposes, but Intuitive Surgical's "competitors" listing includes technology giants Toshiba and Hitachi
This is by far the most defensible moat I've ever seen. Intuitive Surgical's entire management team could disappear or get replaced today, and the business would hardly miss a beat. Since neither of those doomsday scenarios is likely to happen, we're looking at a massive competitive advantage -- because there really is no competition to speak of.
Investing early not only makes the most out of the time value of your money, but also lets you jump aboard growth stocks before they have fully matured. And we're still very early in Intuitive Surgical's remarkable history.
As impressive as the da Vinci's presence is in North America, the company has hardly even touched the rest of the world yet. In the company's most recent quarter, about 80% of new system sales were happening inside American borders, though growth has been strong in Europe as well.
Moreover, system sales are just the beginning of the money-making opportunity. Every system in operation will need disposable instruments and accessories on a regular basis, in the tried-and-true handle and razorblade model. That creates an exponential growth curve as accessory sales will eventually outgrow system sales. In the third quarter of 2010, 37% of total sales came from renewables; that's up from 32% two years ago. You can see where that trend is heading.
Oh, and the FDA keeps expanding the company's addressable market when it approves new procedures.
In short, we're standing in the foothills of a long and profitable climb.
Finally, 2010 was a very forgettable year for this stock. If you bought in a year ago, you're drinking red ink today while the broader market has advanced. Ouch.
That's terrible news for existing shareholders, but great for new investors. Intuitive Surgical has seen sales and profits accelerate over the last four quarters, yet the stock is cheaper now. That's what we call a fire sale, people.
Granted, you might balk at a trailing P/E ratio in the 30s. However, you're paying a premium for an unmatched combination of high growth and tremendous margins. Intuitive has fatter net margins than mature medical giant Medtronic
What it all boils down to
If Warren Buffett thought high-tech medical systems were at all within his circle of competence, I truly believe he'd make a pass at Intuitive Surgical at this juncture. And even if he doesn't, major Berkshire holding Johnson & Johnson
We individual investors have a very different view of Intuitive Surgical than those hapless quasicompetitors: It's the most-recommended stock in the history of our Rule Breakers newsletter, and the second-most profitable after growth phenom Baidu.com. And Intuitive Surgical's stock has never looked cheaper than it does right now.
It's the perfect stock for 2011, in my book, and I'm backing up my words with a real-money position less than 2 months old. I mean serious business here, folks. Please take our Motley Poll then scroll down to leave a comment.
Which is the best stock for 2011? See all 12 candidates here.
Fool contributor Anders Bylund holds no position in any of the companies discussed here. Intuitive Surgical and Baidu are Motley Fool Rule Breakers recommendations. Berkshire Hathaway is a Motley Fool Stock Advisor choice and a Motley Fool Inside Value selection. Johnson & Johnson is a Motley Fool Income Investor pick. The Fool owns shares of Berkshire Hathaway, Johnson & Johnson, and Medtronic. Motley Fool Alpha owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. You can check out Anders' holdings and a concise bio if you like, and The Motley Fool is investors writing for investors.
More from The Motley Fool
Earnings: 2 Hot Stocks to Watch Next Week
These two stocks have soared in the past 12 months. Can they continue to impress investors?
3 Dividend Stocks That Pay Out Over $8 Billion a Year
Can these huge companies keep the big dividend bucks flowing?
Johnson & Johnson Aims to Start 2018 Healthy
Investors have high hopes for the healthcare conglomerate.